HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price

Compass Therapeutics (NASDAQ:CMPX) had its price target increased by HC Wainwright from $10.00 to $24.00 in a report published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

CMPX has been the subject of several other research reports. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective for the company. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Finally, Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $13.38.

Compass Therapeutics Trading Down 9.0 %

Shares of CMPX opened at $1.46 on Friday. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The firm’s fifty day simple moving average is $2.76 and its two-hundred day simple moving average is $2.10. The stock has a market capitalization of $201.89 million, a P/E ratio of -3.95 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Barclays PLC boosted its stake in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after acquiring an additional 356,352 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC increased its position in Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after purchasing an additional 28,589 shares during the last quarter. Finally, Intech Investment Management LLC raised its stake in Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after purchasing an additional 35,632 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.